VANCOUVER, British Columbia--(BUSINESS WIRE)--As a follow up to ProtoKinetix Inc.’s (OTCBB:PKTX) May 23, 2007 press release related to cryopreserved (or frozen) cells treated with AAGP™, in collaboration with the University of Helsinki, Finland, ProtoKinetix has recently finished a set of trials designed to determine whether AAGP™ treated cells could survive after preservation in refrigeration (4°C).
